Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma

Clinical trial NCT01880567 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT01880567
Sponsor: M.D. Anderson Cancer Center
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

CCND1 Positive CCND2 Positive CCND3 Positive CD20 Positive Mantle Cell Lymphoma Recurrent Mantle Cell Lymphoma Refractory Mantle Cell Lymphoma

Start date: 2013-07-15
Primary completion: 2028-07-31
Enrollment: 113

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.